Provectus Biopharmaceuticals (PVCT) 10-Q2020 Q1 Quarterly report

Filed: 13 May 20, 3:14pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: Acad, addressed, adverse, adversely, affirmed, Aid, annum, assevere, ASU, attributable, autolytic, average, beginning, begun, Bruce, carryback, chain, clarification, compartment, confidence, constituted, contractual, COO, coordinated, correlated, CoV, criteria, declared, deduction, deferment, deferral, depository, Dev, directly, Disaster, disbursement, disrupt, disruption, driven, economic, EIDG, EIDL, eligibility, eligible, enactment, ensure, envisioned, evolve, experienced, experiencing, facility, Fahrenbacher, forgivable, full, functional, functioning, gene, global, Gocheva, guidance, health, heightened, holder, Horowitz, ICD, Immunol, induction, ineligible, ingredient, inhibition, Injury, insufficient, interpreted, invasive, judgement, launched, legislation, lending, liver, long, minimize, mNET, monthly, multiple, mUM, myeloid, Nishimura, Occupancy, Oncol, Oral, outbreak, pandemic, Paycheck, permission, Piao, PPP, precautionary, President, progression, prolonged, qualified, qualifying, rate, RB, Recently, refundable, regaining, relief, rely, reportedly, respiratory, Sci, service, side, signaling, sixty, Snyder, social, spread, strain, superficial, Supreme, syndrome, tax, technical, temporary, trading, transformation, Trump, type, uncertain, unforgiven, vaccine, varying, visceral, widespread, World, worldwide

Removed: advisory, agreed, answer, approach, arising, attorney, balance, BHS, Bible, candidate, comparability, comparative, confidential, conform, counsel, denying, disgorgement, enabling, examination, exclusive, expertise, forensic, forthcoming, found, group, hearing, instructed, July, labor, LLP, matter, measure, modified, offset, oncolytic, partially, payment, PC, practical, prejudgment, prior, prominent, reclassified, recognition, recognize, recover, remained, requiring, resolved, retained, retrospective, ROU, RSM, shareholder, Smith, transparency, uncertainty, unchanged, unsubstantiated, vi, xanthene

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

PVCT similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32

CERTIFICATION PURSUANT TO RULE 13a-14(b) UNDER

THE SECURITIES EXCHANGE ACT OF 1934 AND

SECTION 1350 OF CHAPTER 63 OF TITLE 18 OF THE UNITED STATES CODE

Each of the undersigned, Bruce Horowitz, the Chief Operating Officer (principal executive officer) of Provectus Biopharmaceuticals, Inc. (the “Company”), and Heather Raines, CPA, the Chief Financial Officer (principal financial officer) of the Company, certifies, pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code, that (1) this Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act, and (2) the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This Certification is signed on May 13, 2020.

	By:	/s/ Bruce Horowitz
		Bruce Horowitz
		Chief Operating Officer (Principal Executive Officer)

	By:	/s/ Heather Raines
		Heather Raines, CPA
		Chief Financial Officer (Principal Financial Officer)